Zoetis Inc (ZOE MU) stock market data APIs
€121.4478
0(0%)
as of October 17, 2025
Try our APIs with
free plan!
Zoetis Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ZOE.MU.
Prev. Close
121.4478
Open
121.4478
High
121.4478
Low
121.4478
52 wk Range
120.42-173.1241
Market Cap
96 963 M
Dividends (Yield)
0.0115
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Zoetis Inc data using free add-ons & libraries
Get Zoetis Inc Fundamental Data
Zoetis Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Zoetis Inc News
New
Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains?
Xeris Biopharma (XERS) shares ended the last trading session 14.2% higher at $9.27. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. Thi...
How Lenivia Approvals at Zoetis (ZTS) Have Changed Its Innovation Pipeline and Recurring Revenue Outlook
Earlier in October 2025, Zoetis Inc. announced that Health Canada approved Lenivia (izenivetmab injection) for alleviating osteoarthritis pain in dogs, and the European Medicines Agency’s Committee ...
Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs
First long-acting canine anti-nerve growth factor monoclonal antibody therapy administered once every three months Approval marks major milestone in the company’s continued innovation for canine OA ...
Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Zoetis (ZTS). Th...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
